Premium
Evaluating the role of Section 1115 waivers on Medicaid coverage and utilization of opioid agonist therapy among substance use treatment admissions
Author(s) -
Tormohlen Kayla N.,
Krawczyk Noa,
Feder Kenneth A.,
Riehm Kira E.,
Crum Rosa M.,
Mojtabai Ramin
Publication year - 2020
Publication title -
health services research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.706
H-Index - 121
eISSN - 1475-6773
pISSN - 0017-9124
DOI - 10.1111/1475-6773.13250
Subject(s) - medicaid , waiver , medicine , substance abuse treatment , opioid , emergency medicine , substance abuse , family medicine , psychiatry , health care , receptor , political science , law , economics , economic growth
Abstract Objective To examine the impact of Section 1115 waivers on Medicaid coverage and opioid agonist therapy (OAT) utilization among substance use treatment admissions. Data Source Treatment Episode Data Set‐Admissions (TEDS‐A) (2001‐2012). Study Design We examined effects of 1115 waiver implementation on proportions of substance use treatment admissions with Medicaid and receiving OAT, using random intercept linear regression. Principal Findings 1115 waiver implementation was associated with an average of a 6 percentage point increase in proportion of all admissions with Medicaid, and 4 percentage point increase among opioid outpatient admissions. Implementation was not associated with change in proportion of opioid outpatient admissions receiving OAT. Conclusions 1115 waivers influence Medicaid coverage among substance use treatment admissions. The findings improve our understanding of how state policies impact substance use treatment utilization.